Author Archives: Forest Ray PhD

Lung Transplant Biorepository, Registry Targets Patient Outcomes

The Cystic Fibrosis Foundation (CFF) and the Cleveland Clinic are launching the Cystic Fibrosis Lung Transplant Consortium (CFLTC) Biorepository and Registry, aimed at supporting research into understanding the factors that influence lung transplant outcomes. “The biorepository and registry for lung transplant recipients represents an exciting leap forward in…

Claire’s Place Foundation Glow Ride is Aug. 21

The seventh annual Glow Ride for Cystic Fibrosis, hosted by Claire’s Place Foundation, will resume along the coast of Los Angeles, California, on Aug. 21. Last year’s cystic fibrosis (CF) fundraising event was postponed out of consideration for safety measures related to the global COVID-19 pandemic. “Since…

Arrowhead Pauses ARO-ENaC Study Amid Safety Concerns

Arrowhead Pharmaceuticals has voluntarily paused new screening, enrollment, and dosing in its Phase 1/2 trial of ARO-ENaC, an investigational treatment for cystic fibrosis (CF). The decision came after unexpected signs of local lung inflammation occurred in an ongoing chronic toxicology study taking place in rats. “The safety of…

Orkambi Seen on CT Scans to Aid Lung Health, Mucus Clearance

Treatment with Orkambi (ivacaftor/lumacaftor) led to significant improvements in lung health, particularly related to clearing mucus, among people with cystic fibrosis (CF), according to a real-world study of its use in France. The investigation provided a first high-resolution CT scan-based assessment of the medication’s effectiveness, and results also indicated…

Regular, Sustained Exercise Helps in Managing CF, Study Suggests

Physical activity, undertaken regularly over the long term, appears to complement other therapies in managing cystic fibrosis (CF), a study in a group of active and non-active patients found. Its results also showed that tumor necrosis factor alpha (TNF-alpha) may serve as a biomarker of inflammation to monitor the…

EU, UK Considering Expanding Kaftrio to Children Ages 6 and Older

Regulatory agencies in the European Union and in the U.K agreed to consider expanding the use of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to children with cystic fibrosis (CF) who have at least one F508del mutation starting at age 6. The European Medicines Agency (EMA) and the U.K.’s Medicines…

CF Awareness Film Festival Seeks Submissions

People living with cystic fibrosis (CF) are invited to participate in CF Awareness Month by submitting entries for the CF Awareness Film Festival, taking place virtually May 24–31. Supported by the Bonnell Foundation and the I See You Awards, the festival aims to highlight issues faced by…

Coalition Calls for Clear COVID-19 Vaccination Policies

People living with cystic fibrosis (CF) need clear, aggressive, and science-driven COVID-19 vaccine distribution strategies that prioritize their condition, says a coalition of experts. The Global Registry Harmonization Group (GRHG), composed of scientists and patient advocates, including the CF Trust, wrote a letter to the…


Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.